Health News Releases

  • Today May 2
January 26, 2024 11:20
Variational AI Announces Generative AI Project With Merck
Variational AI (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fvariational.ai%2F&esheet=53887584&newsitemid=20240125917133&lan=en-US&anchor=Variational+AI&index=1&md5=29326fc2ebf897
January 26, 2024 09:30
IMCAS 2024: Galderma to Present Latest Updates From Its Unparalleled Aesthetics Portfolio Reinforcing Its Leadership Position
Galderma will be sharing the latest updates from across its broad and unparalleled portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2024 from February 1-3, 2024, in
January 25, 2024 16:05
HD Immune GmbH Foundation and Publication of Latest Pre-Clinical Data
HD Immune GmbH (HDI), a privately held biotechnology company developing novel antibody treatments for Huntington’s Disease, announces commencement of operations by its two founders Dr. Stefan Bartl an
January 25, 2024 15:10
Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of a new sub-brand, RenBiologics™, to represent the company’s antibody discovery business division
Olivier Brandicourt, M.D. (Photo: Business Wire)
January 25, 2024 10:05
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that Olivier Brandicourt, M.D. has been appointed to its Board of Directors. Dr. Brandicourt wil
January 24, 2024 15:20
Crown Bioscience’s Global Oncology Research Facilities Achieve Prestigious ISO and CAP Accreditations
Crown Bioscience (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.crownbio.com%2F&esheet=53885224&newsitemid=20240123812070&lan=en-US&anchor=Crown+Bioscience&index=1&md5=6c8d045a
January 23, 2024 11:50
Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Merck, a leading science and technology company, today announced new real-world data that continue to reinforce the JAVELIN Bladder regimen of first-line platinum-based chemotherapy followed by BAVENC
January 22, 2024 15:35
Galderma Announces Regulatory Approval for Restylane® SHAYPE™, a New Hyaluronic Acid Injectable Designed for Augmenting the Chin Region
Galderma, the emerging pure-play dermatology category leader, announced today it has received approval from Health Canada for Restylane® SHAYPE™, a hyaluronic acid (HA) injectable designed for tempora
January 19, 2024 17:35
New Blue Shift Report From Arthur D. Little Assesses the Future of Synthetic Biology
Arthur D. Little (ADL) has published The Brave New World Of Synthetic Biology, the latest in a series of leading edge reports from the company’s Blue Shift institute, which explore the impact of new t
January 19, 2024 15:40
Fujirebio and Agappe Enter into an Agreement on Business Collaboration in the Field of CLIA Based Immunoassay
Fujirebio Holdings, Inc. and Agappe Diagnostics Ltd today announced that they have entered into an agreement of Contract Development and Manufacturing Organization (CDMO) partnership for Cartridge bas
January 19, 2024 15:00
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the “Board of Directors”) unani
Hypervolt 2 Pro from Hyperice (Photo: Business Wire)
January 19, 2024 14:45
Hyperice Expands IP Enforcement Action, Files Percussion Patent Infringement Lawsuits Against Sharper Image, HoMedics, Ekrin Athletics, and Over a Dozen Others
Hyperice (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhyperice.com%2F&esheet=53883981&newsitemid=20240118052531&lan=en-US&anchor=Hyperice&index=1&md5=50225aea35cb318a90a877e8ce65
January 19, 2024 14:15
ELIQUENT Life Sciences Announces Acquisition of European-Focused Regulatory Partner: RApport Global Strategic Services
ELIQUENT Life Sciences (ELIQUENT), a global regulatory consulting firm for the life sciences industry, today announced the acquisition of RApport Global Strategic Services (RApport). RApport is a UK b
January 19, 2024 11:00
Takeda Named Global Top Employer for Seventh Consecutive Year
Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53884185&newsitemid=20240118372418&lan=en-US&anchor=Takeda&index=1&md5=60021b3805d222a8a4d5481a478ebf
Timeline Longevity Products (Photo: Timeline)
January 18, 2024 16:55
Timeline, a Swiss Longevity Biotech, Secures Pivotal Financing Round with Support from Strategic Global Industry Leaders, including L’Oréal and Nestlé
Timeline, a consumer health biotech company at the forefront of developing innovative solutions for healthy aging and longevity, today announces that it raised CHF 56M (USD 66M) in an oversubscribed S
©PDC*Line
January 18, 2024 15:15
PDC*line Pharma and Partners Receive €8.1M From Walloon Region and Wallonia Health Cluster BioWin for Personalized Therapeutic Vaccine Project
PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancer, announces today the selection of the PDC*neo+ project for funding by
January 17, 2024 15:57
TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously
Galderma announced today positive topline results from the phase III READY-3 clinical trial investigating the use of RelabotulinumtoxinA for the treatment of glabellar lines (frown lines) and lateral
On January 11th, trailblazing medical technology company Xenco Medical unveiled its convergent techn
January 17, 2024 15:55
Xenco Medical Unveils the TrabeculeX Continuum, a Breakthrough Convergence of Digital Health and Biomaterials, at CES 2024 in Las Vegas, the World’s Largest Technology Conference
On January 11th, trailblazing medical technology company Xenco Medical unveiled its convergent technology bridging Digital Health and Biomaterials by showcasing its TrabeculeX Continuum™ at the 2024 C
January 17, 2024 15:30
KBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceutical Companies with Integrated Drug Substance and Drug Product Solutions
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract manufa
January 17, 2024 15:05
Women's Health Remains in Crisis Worldwide Even as COVID-19 Pandemic Wanes
The world faces an emergency in women’s health even as the COVID-19 pandemic wanes, according to one of the largest annual updates on women’s well-being — the Hologic Global Women’s Health Index. W
January 17, 2024 15:05
Parse Biosciences Acquires Biomage
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=53882475&newsitemid=20240116719945&lan=en-US&anchor=Parse+Biosciences&index=1&md
January 17, 2024 14:33
U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53882479&newsitemid=20240115984065&lan=en-US&anchor=TSE%3A4502%2FNYSE%
January 16, 2024 09:40
Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset
Neuraptive Therapeutics Inc., a leader in innovative medical solutions, is pleased to announce that it has received Orphan Drug Designation from the United States (US) Food and Drug Administration (FD
Steve Purtell - Chief Financial Officer, ELIQUENT Life Sciences (Photo: Business Wire)
January 12, 2024 17:40
ELIQUENT Life Sciences Announces Steve Purtell as Chief Financial Officer
ELIQUENT Life Sciences, a global regulatory consulting firm for the life sciences industry, today announced the appointment of Steve Purtell as its new chief financial officer (CFO). This strategic ad
Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC. (Photo:
January 12, 2024 10:20
QPS Significantly Enhances Mass Spectrometry Laboratory Capacity
QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is rapidly expanding its mass
25 per page50 per page75 per page100 per page